Clinical Trial Update: Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated tolerability and antiviral activity of high-dose Favipiravir in semen of Ebola virus survivors; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Favipiravir (favipiravir)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Ebola Virus Survivor | Phase 2 | Status: TERMINATED